The open-label trial tests a 900 mg daily dose of the investigational medication. This clinical push follows the Food and Drug Administration’s decision to grant VS-7375 fast-track designation for patients facing advanced or metastatic pancreatic cancer in both first- and second-line settings.

Michael Kauffman, president of development at Verastem, noted that the company is prioritizing the rapid advancement of the drug across various tumor types where current medical options are nonexistent. The study represents a critical step in addressing a specific genetic mutation that has historically proven difficult to treat.